Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET
Company Participants
Daniel Kontoh-Boateng - Investor Relations
Lisa Ricciardi - President and Chief Executive Officer
John Doyle - Chief Financial Officer
Tony Caggiano - Chief Medical Officer and Head, R&D
Conference Call Participants
Charles Duncan - Cantor
Jay Olson - Oppenheimer
Aydin Huseynov - Ladenburg
Operator
Good morning, ladies and gentlemen and welcome to Cognition Therapeutics Second Quarter 2023 Earnings Conference Call. My name is Jenny and I will be your conference operator today. This call is being recorded. I would like to turn the presentation over now to your host for today’s call, Daniel Kontoh-Boateng, Investor Relations for Cognition Therapeutics. Please proceed, Mr. Kontoh-Boateng.
Daniel Kontoh-Boateng
Good morning and thank you for participating in Cognition Therapeutics conference call today. With me today are Lisa Ricciardi, President and Chief Executive Officer of Cognition Therapeutics and John Doyle, Chief Financial Officer of Cognition.
A press release detailing Cognition Therapeutics’ second quarter 2023 results is available on the Investors section of our website at cogrx.com. We encourage everyone to read this morning’s press release as well as cognitions quarterly report on Form 10-Q, which is now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company’s website and will be archived for 30 days.
Please note certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, management will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company’s business.
These forward-looking statements are qualified by the cautionary statements contained in cognitions press release and SEC filings. Including its quarterly report on Form 10-Q and previous filings. This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Competition undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call.
With that, I would now like to hand the call over to Lisa Ricciardi. Lisa?
Lisa Ricciardi
Thank you, Daniel, and good morning, everyone. Welcome to Cognition Therapeutics earnings conference call covering the results for the second quarter of 2023. On today’s call are Chief Financial Officer, John Doyle, and I will share prepared remarks on the company’s progress and financial performance in 2023, after which we’ll be joined by Dr. Tony Caggiano, our Chief Medical Officer and Head of R&D for questions and answers.